Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-3-27
pubmed:abstractText
In two previous randomized controlled trials we showed that treatment of severe childhood immunoglobulin A nephropathy (IgA-N) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole prevented any increase of sclerosed glomeruli and that prednisolone alone did not prevent a further increase of sclerosed glomeruli. Accordingly, the immunosuppressant is considered to be important. Often, however, we were unable to complete azathioprine regimen due to toxicity. Therefore, a different but effective immunosuppressant may be worth trying. Mizoribine, like azathioprine, is an antimetabolite that exerts its immunosuppressant effect by inhibiting lymphocyte proliferation. In this pilot study, we administered mizoribine instead of azathioprine as part of the combination therapy for treating 23 children with severe IgA-N and evaluated the efficacy and safety. Eighteen patients reached the primary endpoint (urine protein/creatinine ratio <0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by Kaplan-Meier was 80.4%. Median protein excretion was reduced from 1.19 g/m(2)/day to 0.05 g/m(2)/day (p < 0.0001). After treatment, the median percentage of glomeruli showing sclerosis was unchanged in comparison with that before treatment. No patients required a change of treatment. In conclusion, the efficacy and safety of the mizoribine combination seems to be acceptable for treating children with severe IgA-N.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0931-041X
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
757-63
pubmed:meshHeading
pubmed-meshheading:18224343-Biopsy, pubmed-meshheading:18224343-Child, pubmed-meshheading:18224343-Dipyridamole, pubmed-meshheading:18224343-Disease Progression, pubmed-meshheading:18224343-Female, pubmed-meshheading:18224343-Follow-Up Studies, pubmed-meshheading:18224343-Glomerulonephritis, IGA, pubmed-meshheading:18224343-Glucocorticoids, pubmed-meshheading:18224343-Humans, pubmed-meshheading:18224343-IMP Dehydrogenase, pubmed-meshheading:18224343-Immunoglobulin A, pubmed-meshheading:18224343-Immunosuppressive Agents, pubmed-meshheading:18224343-Kidney Glomerulus, pubmed-meshheading:18224343-Male, pubmed-meshheading:18224343-Pilot Projects, pubmed-meshheading:18224343-Platelet Aggregation Inhibitors, pubmed-meshheading:18224343-Prednisolone, pubmed-meshheading:18224343-Prospective Studies, pubmed-meshheading:18224343-Proteinuria, pubmed-meshheading:18224343-Ribonucleosides, pubmed-meshheading:18224343-Severity of Illness Index, pubmed-meshheading:18224343-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.
pubmed:affiliation
Department of Pediatrics, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Japan. nori@wakayama-med.ac.jp
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study